European Commission Authorised GSK's Omjjara (Momelotinib), GSK Seeks EMA Approval to Expand Use of Pioneering RSV Vaccine to Adults Aged 50-59
Portfolio Pulse from Benzinga Newsdesk
GSK plc (NYSE:GSK) received marketing authorization from the European Commission for Omjjara (momelotinib), a treatment for splenomegaly or symptoms in adult patients with certain types of myelofibrosis. GSK is also seeking EMA approval to expand the use of its RSV vaccine to adults aged 50-59.
January 29, 2024 | 11:38 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
GSK plc received EU authorization for Omjjara, a myelofibrosis treatment, and is seeking EMA approval for its RSV vaccine for adults aged 50-59.
The authorization of Omjjara by the European Commission is a significant milestone for GSK, likely to have a positive impact on the stock as it opens up a new market for the drug. Additionally, the potential expansion of the RSV vaccine to a broader age group could further enhance GSK's revenue streams in the near term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100